Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Cetirizine hydrochloride
All products: not a benefit
Apo-Cetirizine · DIN 02231603 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Cetirizine · DIN 02231603
Manufacturer: Apotex Inc.; listing date 2007-12-19
Health Canada: Marketed since 1998-10-21 · brand APO-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Apotex inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02231603)
Source record
DIN 02231603: Apo-Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4083; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231603
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50975
Interchangeable products
Extra Strength Allergy Relief · DIN 02315955 · not recorded
Jamp Cetirizine · DIN 02517566 · not recorded
Jamp-Cetirizine · DIN 02451778 · not recorded
Mar-Cetirizine · DIN 02427133 · not recorded
Nat-Cetirizine · DIN 02496461 · not recorded
Reactine · DIN 02223554 · not recorded
Shortage status: resolved shortage (ended December 9, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231603
Shortage record checked October 6, 2026
Extra Strength Allergy Relief · DIN 02315955 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Extra Strength Allergy Relief · DIN 02315955
Manufacturer: Pharmascience Inc.; listing date 2009-11-13
Health Canada: Marketed since 2012-09-24 · brand EXTRA STRENGTH ALLERGY RELIEF · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Pharmascience inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02315955)
Source record
DIN 02315955: Extra Strength Allergy Relief
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id PMS
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3938; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02315955
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80148
Interchangeable products
Apo-Cetirizine · DIN 02231603 · not recorded
Jamp Cetirizine · DIN 02517566 · not recorded
Jamp-Cetirizine · DIN 02451778 · not recorded
Mar-Cetirizine · DIN 02427133 · not recorded
Nat-Cetirizine · DIN 02496461 · not recorded
Reactine · DIN 02223554 · not recorded
Shortage status: discontinued (March 31, 2017, reported by PHARMASCIENCE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02315955
Shortage record checked October 6, 2026
Jamp-Cetirizine · DIN 02451778 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Cetirizine · DIN 02451778
Manufacturer: Jamp Pharma Corporation; listing date 2016-08-30
Health Canada: Marketed since 2026-03-05 · brand JAMP-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Jamp pharma corporation · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02451778)
Source record
DIN 02451778: Jamp-Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4083; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02451778
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93812
Interchangeable products
Apo-Cetirizine · DIN 02231603 · not recorded
Extra Strength Allergy Relief · DIN 02315955 · not recorded
Jamp Cetirizine · DIN 02517566 · not recorded
Mar-Cetirizine · DIN 02427133 · not recorded
Nat-Cetirizine · DIN 02496461 · not recorded
Reactine · DIN 02223554 · not recorded
Shortage status: active shortage (reported April 12, 2023, estimated to end December 31, 2023, last updated April 13, 2023) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02451778
Shortage record checked October 6, 2026
Nat-Cetirizine · DIN 02496461 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Nat-Cetirizine · DIN 02496461
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-05-29
Health Canada: Marketed since 2020-08-20 · brand NAT-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Natco pharma (canada) inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02496461)
Source record
DIN 02496461: Nat-Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id NAT
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4083; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02496461
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98634
Interchangeable products
Apo-Cetirizine · DIN 02231603 · not recorded
Extra Strength Allergy Relief · DIN 02315955 · not recorded
Jamp Cetirizine · DIN 02517566 · not recorded
Jamp-Cetirizine · DIN 02451778 · not recorded
Mar-Cetirizine · DIN 02427133 · not recorded
Reactine · DIN 02223554 · not recorded
Shortage status: resolved shortage (ended March 4, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02496461
Shortage record checked October 6, 2026
Reactine · DIN 02223554 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Reactine · DIN 02223554
Manufacturer: McNeil Consumer Products Co.; listing date 2007-12-19
Health Canada: Marketed since 2026-03-12 · brand REACTINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Kenvue canada inc. · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product recordReactine: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02223554)
Source record
DIN 02223554: Reactine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id MCL
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02223554
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43370
Interchangeable products
Apo-Cetirizine · DIN 02231603 · not recorded
Extra Strength Allergy Relief · DIN 02315955 · not recorded
Jamp Cetirizine · DIN 02517566 · not recorded
Jamp-Cetirizine · DIN 02451778 · not recorded
Mar-Cetirizine · DIN 02427133 · not recorded
Nat-Cetirizine · DIN 02496461 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02223554
Shortage record checked October 6, 2026
Apo-Cetirizine · DIN 02453363 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Cetirizine · DIN 02453363
Manufacturer: Apotex Inc.; listing date 2016-06-29
Health Canada: Marketed since 2016-04-22 · brand APO-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02453363)
Source record
DIN 02453363: Apo-Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id APX
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7535; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02453363
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93991
Interchangeable products
Cetirizine · DIN 02515695 · not recorded
Cetirizine · DIN 02534126 · not recorded
Jamp Cetirizine Tablets · DIN 02517353 · not recorded
Jamp-Cetirizine · DIN 02466171 · not recorded
M-Cetirizine · DIN 02512025 · not recorded
Mar-Cetirizine · DIN 02427141 · not recorded
Mint-Cetirizine · DIN 02491125 · not recorded
NRA-Cetirizine · DIN 02521806 · not recorded
NRA-Cetirizine Tablets · DIN 02530236 · not recorded
Nat-Cetirizine · DIN 02496488 · not recorded
PMS-Cetirizine · DIN 02315963 · not recorded
Reactine · DIN 01900978 · not recorded
Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: resolved shortage (ended March 31, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453363
Shortage record checked October 6, 2026
Cetirizine · DIN 02515695 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Cetirizine · DIN 02515695
Manufacturer: Sanis Health Inc.; listing date 2021-07-30
Health Canada: Marketed since 2025-08-08 · brand CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02515695)
Source record
DIN 02515695: Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id SAI
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7535; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02515695
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100508
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded
Cetirizine · DIN 02534126 · not recorded
Jamp Cetirizine Tablets · DIN 02517353 · not recorded
Jamp-Cetirizine · DIN 02466171 · not recorded
M-Cetirizine · DIN 02512025 · not recorded
Mar-Cetirizine · DIN 02427141 · not recorded
Mint-Cetirizine · DIN 02491125 · not recorded
NRA-Cetirizine · DIN 02521806 · not recorded
NRA-Cetirizine Tablets · DIN 02530236 · not recorded
Nat-Cetirizine · DIN 02496488 · not recorded
PMS-Cetirizine · DIN 02315963 · not recorded
Reactine · DIN 01900978 · not recorded
Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02515695
Shortage record checked October 6, 2026
Cetirizine · DIN 02534126 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Cetirizine · DIN 02534126
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2023-09-28
Health Canada: Marketed since 2023-07-20 · brand CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02534126)
Source record
DIN 02534126: Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id SIV
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7535; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02534126
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102306
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded
Cetirizine · DIN 02515695 · not recorded
Jamp Cetirizine Tablets · DIN 02517353 · not recorded
Jamp-Cetirizine · DIN 02466171 · not recorded
M-Cetirizine · DIN 02512025 · not recorded
Mar-Cetirizine · DIN 02427141 · not recorded
Mint-Cetirizine · DIN 02491125 · not recorded
NRA-Cetirizine · DIN 02521806 · not recorded
NRA-Cetirizine Tablets · DIN 02530236 · not recorded
Nat-Cetirizine · DIN 02496488 · not recorded
PMS-Cetirizine · DIN 02315963 · not recorded
Reactine · DIN 01900978 · not recorded
Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534126
Shortage record checked October 6, 2026
Jamp-Cetirizine · DIN 02466171 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp-Cetirizine · DIN 02466171
Manufacturer: Jamp Pharma Corporation; listing date 2017-10-30
Health Canada: Marketed since 2025-12-15 · brand JAMP-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02466171)
Source record
DIN 02466171: Jamp-Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id JPC
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7535; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02466171
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95446
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded
Cetirizine · DIN 02515695 · not recorded
Cetirizine · DIN 02534126 · not recorded
Jamp Cetirizine Tablets · DIN 02517353 · not recorded
M-Cetirizine · DIN 02512025 · not recorded
Mar-Cetirizine · DIN 02427141 · not recorded
Mint-Cetirizine · DIN 02491125 · not recorded
NRA-Cetirizine · DIN 02521806 · not recorded
NRA-Cetirizine Tablets · DIN 02530236 · not recorded
Nat-Cetirizine · DIN 02496488 · not recorded
PMS-Cetirizine · DIN 02315963 · not recorded
Reactine · DIN 01900978 · not recorded
Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: resolved shortage (ended June 13, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466171
Shortage record checked October 6, 2026
M-Cetirizine · DIN 02512025 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
M-Cetirizine · DIN 02512025
Manufacturer: Mantra Pharma Inc.; listing date 2021-11-30
Health Canada: Marketed since 2021-04-20 · brand M-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02512025)
Source record
DIN 02512025: M-Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id MAT
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7535; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02512025
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100119
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded
Cetirizine · DIN 02515695 · not recorded
Cetirizine · DIN 02534126 · not recorded
Jamp Cetirizine Tablets · DIN 02517353 · not recorded
Jamp-Cetirizine · DIN 02466171 · not recorded
Mar-Cetirizine · DIN 02427141 · not recorded
Mint-Cetirizine · DIN 02491125 · not recorded
NRA-Cetirizine · DIN 02521806 · not recorded
NRA-Cetirizine Tablets · DIN 02530236 · not recorded
Nat-Cetirizine · DIN 02496488 · not recorded
PMS-Cetirizine · DIN 02315963 · not recorded
Reactine · DIN 01900978 · not recorded
Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02512025
Shortage record checked October 6, 2026
Mar-Cetirizine · DIN 02427141 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mar-Cetirizine · DIN 02427141
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-10-29
Health Canada: Marketed since 2015-10-13 · brand MAR-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02427141)
Source record
DIN 02427141: Mar-Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id MAR
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7535; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02427141
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91167
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded
Cetirizine · DIN 02515695 · not recorded
Cetirizine · DIN 02534126 · not recorded
Jamp Cetirizine Tablets · DIN 02517353 · not recorded
Jamp-Cetirizine · DIN 02466171 · not recorded
M-Cetirizine · DIN 02512025 · not recorded
Mint-Cetirizine · DIN 02491125 · not recorded
NRA-Cetirizine · DIN 02521806 · not recorded
NRA-Cetirizine Tablets · DIN 02530236 · not recorded
Nat-Cetirizine · DIN 02496488 · not recorded
PMS-Cetirizine · DIN 02315963 · not recorded
Reactine · DIN 01900978 · not recorded
Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: resolved shortage (ended June 5, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02427141
Shortage record checked October 6, 2026
NRA-Cetirizine Tablets · DIN 02530236 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
NRA-Cetirizine Tablets · DIN 02530236
Manufacturer: Nora Pharma; listing date 2023-05-31
Health Canada: Marketed since 2023-04-13 · brand NRA-CETIRIZINE TABLETS · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02530236)
Source record
DIN 02530236: NRA-Cetirizine Tablets
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id NRA
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7535; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02530236
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101942
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded
Cetirizine · DIN 02515695 · not recorded
Cetirizine · DIN 02534126 · not recorded
Jamp Cetirizine Tablets · DIN 02517353 · not recorded
Jamp-Cetirizine · DIN 02466171 · not recorded
M-Cetirizine · DIN 02512025 · not recorded
Mar-Cetirizine · DIN 02427141 · not recorded
Mint-Cetirizine · DIN 02491125 · not recorded
NRA-Cetirizine · DIN 02521806 · not recorded
Nat-Cetirizine · DIN 02496488 · not recorded
PMS-Cetirizine · DIN 02315963 · not recorded
Reactine · DIN 01900978 · not recorded
Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02530236
Shortage record checked October 6, 2026
Nat-Cetirizine · DIN 02496488 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Nat-Cetirizine · DIN 02496488
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-05-29
Health Canada: Marketed since 2020-08-19 · brand NAT-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Natco pharma (canada) inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02496488)
Source record
DIN 02496488: Nat-Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id NAT
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7535; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02496488
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98635
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded
Cetirizine · DIN 02515695 · not recorded
Cetirizine · DIN 02534126 · not recorded
Jamp Cetirizine Tablets · DIN 02517353 · not recorded
Jamp-Cetirizine · DIN 02466171 · not recorded
M-Cetirizine · DIN 02512025 · not recorded
Mar-Cetirizine · DIN 02427141 · not recorded
Mint-Cetirizine · DIN 02491125 · not recorded
NRA-Cetirizine · DIN 02521806 · not recorded
NRA-Cetirizine Tablets · DIN 02530236 · not recorded
PMS-Cetirizine · DIN 02315963 · not recorded
Reactine · DIN 01900978 · not recorded
Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: resolved shortage (ended March 4, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02496488
Shortage record checked October 6, 2026
PMS-Cetirizine · DIN 02315963 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Cetirizine · DIN 02315963
Manufacturer: Pharmascience Inc.; listing date 2008-12-23
Health Canada: Marketed since 2008-10-14 · brand PMS-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02315963)
Source record
DIN 02315963: PMS-Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id PMS
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7535; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02315963
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80149
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded
Cetirizine · DIN 02515695 · not recorded
Cetirizine · DIN 02534126 · not recorded
Jamp Cetirizine Tablets · DIN 02517353 · not recorded
Jamp-Cetirizine · DIN 02466171 · not recorded
M-Cetirizine · DIN 02512025 · not recorded
Mar-Cetirizine · DIN 02427141 · not recorded
Mint-Cetirizine · DIN 02491125 · not recorded
NRA-Cetirizine · DIN 02521806 · not recorded
NRA-Cetirizine Tablets · DIN 02530236 · not recorded
Nat-Cetirizine · DIN 02496488 · not recorded
Reactine · DIN 01900978 · not recorded
Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: resolved shortage (ended December 4, 2017); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02315963
Shortage record checked October 6, 2026
Reactine · DIN 01900978 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Reactine · DIN 01900978
Manufacturer: McNeil Consumer Products Co.; listing date 2008-12-23
Health Canada: Marketed since 2026-04-17 · brand REACTINE 20 MG TABLET · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Kenvue canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordReactine: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01900978)
Source record
DIN 01900978: Reactine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id MCL
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01900978
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=46803
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded
Cetirizine · DIN 02515695 · not recorded
Cetirizine · DIN 02534126 · not recorded
Jamp Cetirizine Tablets · DIN 02517353 · not recorded
Jamp-Cetirizine · DIN 02466171 · not recorded
M-Cetirizine · DIN 02512025 · not recorded
Mar-Cetirizine · DIN 02427141 · not recorded
Mint-Cetirizine · DIN 02491125 · not recorded
NRA-Cetirizine · DIN 02521806 · not recorded
NRA-Cetirizine Tablets · DIN 02530236 · not recorded
Nat-Cetirizine · DIN 02496488 · not recorded
PMS-Cetirizine · DIN 02315963 · not recorded
Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01900978
Shortage record checked October 6, 2026
Teva-Cetirizine · DIN 02528681 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Cetirizine · DIN 02528681
Manufacturer: Teva Canada Limited; listing date 2022-11-30
Health Canada: Marketed since 2023-02-24 · brand TEVA-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02528681)
Source record
DIN 02528681: Teva-Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id TEV
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7535; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02528681
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101788
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded
Cetirizine · DIN 02515695 · not recorded
Cetirizine · DIN 02534126 · not recorded
Jamp Cetirizine Tablets · DIN 02517353 · not recorded
Jamp-Cetirizine · DIN 02466171 · not recorded
M-Cetirizine · DIN 02512025 · not recorded
Mar-Cetirizine · DIN 02427141 · not recorded
Mint-Cetirizine · DIN 02491125 · not recorded
NRA-Cetirizine · DIN 02521806 · not recorded
NRA-Cetirizine Tablets · DIN 02530236 · not recorded
Nat-Cetirizine · DIN 02496488 · not recorded
PMS-Cetirizine · DIN 02315963 · not recorded
Reactine · DIN 01900978 · not recorded
Shortage status: resolved shortage (ended September 10, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02528681
Shortage record checked October 6, 2026
Jamp Cetirizine · DIN 02517566 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitDormant since August 3, 2026 · checked October 5, 2026 · What does dormant mean? StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Cetirizine · DIN 02517566
Manufacturer: Jamp Pharma Corporation; listing date 2022-07-29
Health Canada: Dormant since 2026-08-03 · brand CETIRIZINE EXTRA STRENGTH · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Jamp pharma corporation · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02517566)
Source record
DIN 02517566: Jamp Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4083; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02517566
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100694
Interchangeable products
Apo-Cetirizine · DIN 02231603 · not recorded
Extra Strength Allergy Relief · DIN 02315955 · not recorded
Jamp-Cetirizine · DIN 02451778 · not recorded
Mar-Cetirizine · DIN 02427133 · not recorded
Nat-Cetirizine · DIN 02496461 · not recorded
Reactine · DIN 02223554 · not recorded
Shortage status: resolved shortage (ended January 3, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02517566
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 3, 2026 — choose a marketed DIN from the same-category list.
Mar-Cetirizine · DIN 02427133 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitDormant since May 4, 2022 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Cetirizine · DIN 02427133
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-10-29
Health Canada: Dormant since 2022-05-04 · brand MAR-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Marcan pharmaceuticals inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02427133)
Source record
DIN 02427133: Mar-Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id MAR
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4083; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02427133
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91166
Interchangeable products
Apo-Cetirizine · DIN 02231603 · not recorded
Extra Strength Allergy Relief · DIN 02315955 · not recorded
Jamp Cetirizine · DIN 02517566 · not recorded
Jamp-Cetirizine · DIN 02451778 · not recorded
Nat-Cetirizine · DIN 02496461 · not recorded
Reactine · DIN 02223554 · not recorded
Shortage status: resolved shortage (ended March 24, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02427133
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since May 4, 2022 — choose a marketed DIN from the same-category list.
Jamp Cetirizine Tablets · DIN 02517353 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitDormant since August 3, 2026 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp Cetirizine Tablets · DIN 02517353
Manufacturer: Jamp Pharma Corporation; listing date 2022-05-31
Health Canada: Dormant since 2026-08-03 · brand JAMP CETIRIZINE TABLETS · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02517353)
Source record
DIN 02517353: Jamp Cetirizine Tablets
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id JPC
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7535; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02517353
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100677
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded
Cetirizine · DIN 02515695 · not recorded
Cetirizine · DIN 02534126 · not recorded
Jamp-Cetirizine · DIN 02466171 · not recorded
M-Cetirizine · DIN 02512025 · not recorded
Mar-Cetirizine · DIN 02427141 · not recorded
Mint-Cetirizine · DIN 02491125 · not recorded
NRA-Cetirizine · DIN 02521806 · not recorded
NRA-Cetirizine Tablets · DIN 02530236 · not recorded
Nat-Cetirizine · DIN 02496488 · not recorded
PMS-Cetirizine · DIN 02315963 · not recorded
Reactine · DIN 01900978 · not recorded
Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: resolved shortage (ended December 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02517353
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 3, 2026 — choose a marketed DIN from the same-category list.
Mint-Cetirizine · DIN 02491125 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitDormant since January 22, 2023 · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mint-Cetirizine · DIN 02491125
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-02-28
Health Canada: Dormant since 2023-01-22 · brand MINT-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02491125)
Source record
DIN 02491125: Mint-Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id MIN
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7535; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02491125
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98114
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded
Cetirizine · DIN 02515695 · not recorded
Cetirizine · DIN 02534126 · not recorded
Jamp Cetirizine Tablets · DIN 02517353 · not recorded
Jamp-Cetirizine · DIN 02466171 · not recorded
M-Cetirizine · DIN 02512025 · not recorded
Mar-Cetirizine · DIN 02427141 · not recorded
NRA-Cetirizine · DIN 02521806 · not recorded
NRA-Cetirizine Tablets · DIN 02530236 · not recorded
Nat-Cetirizine · DIN 02496488 · not recorded
PMS-Cetirizine · DIN 02315963 · not recorded
Reactine · DIN 01900978 · not recorded
Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02491125
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since January 22, 2023 — choose a marketed DIN from the same-category list.
NRA-Cetirizine · DIN 02521806 · 20 mg · tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-18 — choose a marketed DIN from the same-category list.Discontinued July 18, 2023 · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-07-18 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
NRA-Cetirizine · DIN 02521806
Manufacturer: Nora Pharma; listing date 2022-05-31
Health Canada: Cancelled post market since 2023-07-18 · brand NRA-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02521806)
Source record
DIN 02521806: NRA-Cetirizine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id NRA
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.7535; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02521806
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101099
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded
Cetirizine · DIN 02515695 · not recorded
Cetirizine · DIN 02534126 · not recorded
Jamp Cetirizine Tablets · DIN 02517353 · not recorded
Jamp-Cetirizine · DIN 02466171 · not recorded
M-Cetirizine · DIN 02512025 · not recorded
Mar-Cetirizine · DIN 02427141 · not recorded
Mint-Cetirizine · DIN 02491125 · not recorded
NRA-Cetirizine Tablets · DIN 02530236 · not recorded
Nat-Cetirizine · DIN 02496488 · not recorded
PMS-Cetirizine · DIN 02315963 · not recorded
Reactine · DIN 01900978 · not recorded
Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02521806
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 18, 2023 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (R06A): coverage varies; not interchangeable
- Bilastine (Jamp Bilastine Oral Solution): not a benefit
- Loratadine (Claritin): not a benefit
- Rupatadine (Rupall): not a benefit
Other review policies
For Apo-Cetirizine, Extra Strength Allergy Relief, Jamp-Cetirizine, Nat-Cetirizine, Reactine, Cetirizine, M-Cetirizine, Mar-Cetirizine, NRA-Cetirizine Tablets, PMS-Cetirizine, Teva-Cetirizine, Jamp Cetirizine, Jamp Cetirizine Tablets, Mint-Cetirizine, NRA-Cetirizine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
Ontario source; updated September 15, 2026
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.
Ontario source; updated September 15, 2026